Antithrombotic Therapy in Valvular Heart Disease

  • Steven Droogmans
  • Simon Vanhentenrijk
  • Bernard CosynsEmail author


Patients with valvular heart disease (VHD) are at increased risk for thrombo-emboligenic events and often require antithrombotic therapy. This needs to be clearly weighted against the bleeding risk as this is often also increased. This chapter will provide an overview of current evidence available in patients with VHD. We will discuss general indications of antithrombotic therapy, its duration, dose, bridging during procedures and treatment options during pregnancy.


Antithrombotic therapy Indications Bridging Pregnancy Native VHD Prosthetic VHD Rheumatic VHD Endocarditis Valvular thrombosis 


  1. 1.
    Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefGoogle Scholar
  2. 2.
    Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease—current management and future challenges. Lancet. 2016;387(10025):1324–34.CrossRefGoogle Scholar
  3. 3.
    Lavall D, Hagendorff A, Schirmer SH, et al. Mitral valve interventions in heart failure. ESC Heart Fail. 2018;5(4):552–61.CrossRefGoogle Scholar
  4. 4.
    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2017;38(27):2137–49.PubMedGoogle Scholar
  5. 5.
    Lip GYH, Jensen M, Melgaard L, et al. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating ‘valvular heart disease’ in a nationwide cohort study. Europace. 2019;21(1):33–40.CrossRefGoogle Scholar
  6. 6.
    Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease. Chest. 2012;141:e576S–600S.CrossRefGoogle Scholar
  7. 7.
    Shaw TR, Northridge DB, Sutaria N. Mitral balloon valvotomy and left atrial thrombus. Heart. 2005;91(8):1088–9.CrossRefGoogle Scholar
  8. 8.
    Drobinski G, Montalescot G, Evans J, et al. Systemic embolism as a complication of percutaneous mitral valvuloplasty. Cathet Cardiovasc Diagn. 1992;25(4):327–30.CrossRefGoogle Scholar
  9. 9.
    Kang DH, Song JK, Chae JK, et al. Comparison of outcomes of percutaneous mitral valvuloplasty versus mitral valve replacement after resolution of left atrial appendage thrombi by warfarin therapy. Am J Cardiol. 1998;81(1):97–100.CrossRefGoogle Scholar
  10. 10.
    Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation. 2014;129(21):2158–70.CrossRefGoogle Scholar
  11. 11.
    Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging. 2008;1:133–41.CrossRefGoogle Scholar
  12. 12.
    Barnett HJ, Boughner DR, Taylor DW, et al. Further evidence relating mitral-valve prolapse to cerebral ischemic events. N Engl J Med. 1980;302:139–44.CrossRefGoogle Scholar
  13. 13.
    Gilon D, Buonanno FS, Joffe MM, et al. Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med. 1999;341:8–13.CrossRefGoogle Scholar
  14. 14.
    Leitman M, Tyomkin V, Peleg E, et al. Clinical significance and prevalence of valvular strands during routine echo examinations. Eur Heart J Cardiovasc Imaging. 2014;15(11):1226–30.CrossRefGoogle Scholar
  15. 15.
    Roldan CA, Shively BK, Crawford MH. Valve excrescences: prevalence, evolution and risk for cardioembolism. J Am Coll Cardiol. 1997;30(5):1308–14.CrossRefGoogle Scholar
  16. 16.
    Freedberg RS, Goodkin GM, Perez JL, et al. Valve strands are strongly associated with systemic embolization: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;26(7):1709–12.CrossRefGoogle Scholar
  17. 17.
    Cevik C, Otahbachi M, Nugent K, et al. Mitral regurgitation reduces systemic coagulation activity in patients with rheumatic heart disease. J Heart Valve Dis. 2009;18(3):278–83.PubMedGoogle Scholar
  18. 18.
    Asgar AW, Mack MJ, Stone GW, et al. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231–48.CrossRefGoogle Scholar
  19. 19.
    Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral annulus calcification. J Am Coll Cardiol. 2015;66(17):1934–41.CrossRefGoogle Scholar
  20. 20.
    Benjamin EJ, Plehn JF, D’Agostino RB, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med. 1992;327:374–9.CrossRefGoogle Scholar
  21. 21.
    Eischer JC, Soto FX, DeNaidai L, et al. Possible association of thrombotic, nonbacterial vegetations of the mitral ring: mitral annular calcium and stroke. Am J Cardiol. 1997;79:1712–5.CrossRefGoogle Scholar
  22. 22.
    Mohan JC, Shukla M, Mohan V, et al. Mobile thrombus originating from densely calcified mitral annulus with cerebral embolism. Indian Heart J. 2016;68(Suppl 2):S131–4.CrossRefGoogle Scholar
  23. 23.
    Roberts WC. Valvular, subvalvular and supravalvular aortic stenosis. Morphologic features. Cardiovasc Clin. 1993;5(1):97.Google Scholar
  24. 24.
    Kawahira Y, Kishimoto H, Lio M. Spontaneous aortic thrombosis in a neonate with multiple thrombi in the main branches of the abdominal aorta. Cardiovasc Surg. 1995;3(2):219–21.CrossRefGoogle Scholar
  25. 25.
    Méndez RJ, Cianciulli TF, Parisi CE, et al. Recurrent systemic embolism caused by thrombosis in a stenotic bicuspid aortic valve. Eur J Echocardiogr. 2008;9(1):196–8.CrossRefGoogle Scholar
  26. 26.
    Goldbarg SH, Elmariah S, Miller MA, et al. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007;50(13):1205–13.CrossRefGoogle Scholar
  27. 27.
    Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–91.CrossRefGoogle Scholar
  28. 28.
    Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circulation. 2005;112(1):125–34.CrossRefGoogle Scholar
  29. 29.
    Paolillo V, Gastaldo D, Barretta A, et al. Idiopathic organized thrombus of the tricuspid valve mimicking valvular tumor. Tex Heart Inst J. 2004;31:192–3.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Konishi H, Fukuda M, Kato M, et al. Organized thrombus of the tricuspid valve mimicking valvular tumor. Ann Thorac Surg. 2001;71:2022–4.CrossRefGoogle Scholar
  31. 31.
    Saxena P, Mejia R, Tam RK. A rare presentation of tricuspid valve thrombus in a normal heart. Ann Thorac Surg. 2005;80:1498–500.CrossRefGoogle Scholar
  32. 32.
    Basarici I, Belgi A, Yalcinkaya S. Tricuspid valve thrombus: a case report associated with gonadotropin-releasing hormone analogue therapy and review of the literature. Can J Cardiol. 2008;24(5):401–3.CrossRefGoogle Scholar
  33. 33.
    Angelos G, et al. Mobile pulmonary valve thrombus as a cause of chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2008;129(3):e81–3.CrossRefGoogle Scholar
  34. 34.
    Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet (London, England). 2017;389(10087):2383–92. Scholar
  35. 35.
    Laplace G, Lafitte S, Labèque J-N, et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol. 2004;43(7):1283–90. Scholar
  36. 36.
    Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol. 1999;84(8):905–8.CrossRefGoogle Scholar
  37. 37.
    Goldhaber SZ. “Bridging” and mechanical heart valves: perils, promises, and predictions. Circulation. 2006;113(4):470–2. Scholar
  38. 38.
    Généreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64(24):2605–15. Scholar
  39. 39.
    Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230–68. Scholar
  40. 40.
    Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol. 2012;28(5):520–8. Scholar
  41. 41.
    Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the arte (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10(13):1357–65. Scholar
  42. 42.
    Collet J-P, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. 2018;200:44–50. Scholar
  43. 43.
    Windecker S, Tijssen J, Giustino G, et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J. 2017;184:81–7. Scholar
  44. 44.
    Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015;8(4):e001779–e001779.
  45. 45.
    Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–29. Scholar
  46. 46.
    Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89. Scholar
  47. 47.
    Keuleers S, Herijgers P, Herregods M-C, et al. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011;107(2):275–9. Scholar
  48. 48.
    Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol. 2004;43(1):77–84.CrossRefGoogle Scholar
  49. 49.
    Özkan M, Gündüz S, Biteker M, et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013;6(2):206–16. Scholar
  50. 50.
    Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24. Scholar
  51. 51.
    Jander N, Kienzle R-P, Kayser G, Neumann F-J, Gohlke-Baerwolf C, Minners J. Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol. 2012;109(2):257–62. Scholar
  52. 52.
    Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162–70. Scholar
  53. 53.
    Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation. 2010;121(16):1848–57. Scholar
  54. 54.
    Phan K, Zhao D-F, Wang N, Huo YR, Di Eusanio M, Yan TD. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. J Thorac Dis. 2016;8(1):E83–93. Scholar
  55. 55.
    Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075–128. Scholar
  56. 56.
    Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e495S–530S. Scholar
  57. 57.
    Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis. 2007;44(9):1180–6. Scholar
  58. 58.
    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–86. Scholar
  59. 59.
    Anavekar NS, Schultz JC, De Sa DDC, et al. Modifiers of symptomatic embolic risk in infective endocarditis. Mayo Clin Proc. 2011;86(11):1068–74. Scholar
  60. 60.
    Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med. 1999;159(5):473–5.CrossRefGoogle Scholar
  61. 61.
    Asaithambi G, Adil MM, Qureshi AI. Thrombolysis for ischemic stroke associated with infective endocarditis: results from the nationwide inpatient sample. Stroke. 2013;44(10):2917–9. Scholar
  62. 62.
    Scott WR, New PF, Davis KR, Schnur JA. Computerized axial tomography of intracerebral and intraventricular hemorrhage. Radiology. 1974;112(1):73–80. Scholar
  63. 63.
    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147–97.CrossRefGoogle Scholar
  64. 64.
    D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, Sermer M, Shehata N. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017;38:1509–16.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Steven Droogmans
    • 1
    • 2
  • Simon Vanhentenrijk
    • 1
  • Bernard Cosyns
    • 1
    • 2
    Email author
  1. 1.Centrum voor Vaat en Hartziekten (CHVZ), Universitair Ziekenhuis Brussel (UZB), Vrij Universiteit van BrusselBrusselsBelgium
  2. 2.In Vivo Molecular and Cellular Imaging (ICMI) CenterBrusselsBelgium

Personalised recommendations